1. Introduction {#sec1}
===============

Gastric cancer is one of the most common malignant tumors and the second leading cause of cancer-related deaths worldwide. Indeed, gastric cancer has one of the highest mortality rates of all cancer types and a high incidence in Asia \[[@B1]\]. Nearly three-quarters of cases occur in developing countries, and almost half of all cases occur in East Asia, mainly in China \[[@B2]\]. Because gastric cancer is an aggressive disease with nonspecific early symptoms, it is typically diagnosed only at an advanced stage \[[@B3], [@B4]\].

There are many established treatments for gastric cancer \[[@B3]\], of which surgery remains the most important for patients without major metastasis \[[@B5]\]. However, despite progress in surgical techniques, the overall 5-year survival rate for gastric cancer patients is low while the cost of treatment is high \[[@B6]\]. To improve the early diagnosis rate, the identification of biomarkers of gastric cancer is important \[[@B7]\]. Like other cancers, gastric cancer is a complex and heterogeneous disease. The development and progression of gastric cancer is associated with epigenetic mechanisms, especially DNA methylation \[[@B8], [@B9]\]. Epigenetic alterations such as changes in DNA methylation and histone acetylation/methylation are common in many cancers \[[@B10]\].

The best characterized mechanism is transcriptional silencing events, associated with hypermethylation of the promoter regions of genes that regulate important cell functions \[[@B11]\]. DNA methylation and related chromatin changes are important processes in the regulation of gene expression. Studies of various types of cancer have demonstrated the relevance of these regulatory changes. Promoter hypermethylation of tumor suppressor and tumor-related genes, including*APC*,*hMLH1*,*RUNX3*,*CACNA2D3*,*DKK-3*,*Cystatin*,*CBS*,*GPX3*, and*MYO1A*, has also been observed in gastric cancer \[[@B12]--[@B20]\]. Gene promoter hypermethylation has been examined by methylation-specific PCR (MSP) and bisulfite genomic sequencing (BGS) in human gastric cancer tissues.

The*Nell-1* gene has been mapped to chromosome 11p15 \[[@B21]\]; the high prevalence of*Nell-1* promoter methylation in colon cancer suggests a role for inactivation of the gene in colon tumorigenesis. Additionally,*Nell-1* is a candidate tumor suppressor gene \[[@B22]\].*Nell-1* promoter hypermethylation is a common, tissue-specific event in human esophageal adenocarcinoma (EAC), and it is a potential biomarker of a poor prognosis in early-stage EAC \[[@B23]\]. Based on these findings, we hypothesized that*Nell-1* is inactivated via promoter hypermethylation in human gastric cancer and that this modification may be used as a biomarker for early detection of the disease.

Mass spectrometry (MS) can discriminate between methylated and nonmethylated samples and identify differentially methylated sites with rapidness and accuracy. Matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) MS and the MassCLEAVE reagent (Sequenom, San Diego, CA) are used for the high-throughput quantitative analysis of DNA methylation status in the Sequenom EpiTYPER assay \[[@B24], [@B25]\]. The utility of this method for quantifying methylated and unmethylated DNA molecules was confirmed by the Sequenom group \[[@B26]\].

To assess whether*Nell-1* is inactivated via promoter hypermethylation in human gastric cancer, we investigated the methylation status of the*Nell-1* promoter in 75 samples from 25 patients using MALDI-TOF MS. Our results show that*Nell-1* promoter hypermethylation is a common event in gastric cancer.

2. Materials and Methods {#sec2}
========================

2.1. Sample Collection {#sec2.1}
----------------------

In the current study, 25 gastric cancer tissues, 25 paracarcinoma tissues (3 cm from the tumor margin), 25 normal tissues, and 25 formalin-fixed paraffin wax-embedded gastric cancer tissues and normal tissues were collected from 25 gastric cancer patients who were diagnosed and underwent surgery at the Fourth Affiliated Hospital, Harbin Medical University (Harbin, China), between April and September of 2012. The patients\' characteristics are shown in [Table 1](#tab1){ref-type="table"}. All primary gastric cancers were evaluated according to the criteria set forth in the 7th edition of the American Joint Committee on Cancer Staging Manual. The diagnosis of primary gastric cancer was confirmed by hematoxylin and eosin (H&E) staining. The "normal" gastric tissues in this study were histologically verified to have no neoplastic changes.

Fresh tissue samples were obtained during resection surgery, immediately snap-frozen in liquid nitrogen, and stored at −80°C until they were used for DNA extraction. In this study, none of the patients received chemotherapy or radiation therapy before surgery. The primary gastric cancer tissue, tissue adjacent to the gastric cancer, and normal tissue from each patient were allocated to the gastric, paracarcinoma, and normal groups, respectively.

All participants provided informed consent prior to their participation in the study. All procedures were approved by the ethics committees of the hospitals involved.

2.2. Immunohistochemistry (IHC) and H&E Staining {#sec2.2}
------------------------------------------------

Formalin-fixed, paraffin wax-embedded gastric cancer tissues and normal tissues were used for IHC and H&E staining. For IHC, tissues were fixed in 10% methanol/buffered formalin for 12 h and were processed routinely. The paraffin wax-embedded sections (4 *μ*m) were immersed in xylene and rehydrated through an ethanol series. Endogenous peroxidase activity was blocked by incubating the sections in 3% H~2~O~2~ for 15 min. After washing with phosphate-buffered saline (PBS), the sections were subsequently submerged in EDTA (pH 9) and exposed to microwave heating for antigen retrieval, followed by 3 min of treatment in a prewarmed pressure cooker with antigen retrieval citrate buffer (pH 6.8). Following depressurization, cold water was poured into the cooker for 10 min. The sections were then washed three times with PBS and incubated in goat serum for 20 min. The slides were immersed in anti-*Nell-1* rabbit polyclonal antibodies for 1 h. After washing with PBS, the slides were incubated with horseradish peroxidase-conjugated anti-rabbit antibodies for 1 h. The slides were then examined under a microscope.

2.3. DNA Extraction {#sec2.3}
-------------------

For DNA extraction, frozen tissues were obtained and reviewed to confirm that the tumor content was \>80% of the section area. DNA was extracted from the frozen tissues using a QIAamp DNA Mini Kit (Qiagen AG, Basel, Switzerland) following the manufacturer\'s protocol; the DNA samples were dissolved in a final volume of 100 *μ*L. The quantity of DNA (A260/A280) in each sample was measured using a NanoDrop 2100 spectrophotometer before sequencing (Thermo Fisher Scientific, Waltham, MA).

2.4. Real-Time PCR Analysis {#sec2.4}
---------------------------

Total RNA was extracted from normal and gastric cancer tissues using TRIZOL reagent (Invitrogen, Carlsbad, CA). Agarose gel electrophoresis and a NanoDrop 2000 spectrophotometer (Thermo Fisher Scientific) were employed to assess the quality and concentration of RNA. A total of 1 *μ*g of high-quality RNA was reverse-transcribed to first-strand cDNA with Superscript First-Strand Synthesis SuperMix (Invitrogen). Real-time PCR was conducted with SYBR Green Master mix (Applied Biosystems, Foster City, CA). The reaction (95°C for 15 s and 60°C for 1 min) was run using the ABI PRISM 7500 Real-Time PCR System (Applied Biosystems) with relative expression analyzed by the 2^−ΔΔCt^ method. The sequences of the primers used to amplify*Nell-1* and the control gene*GAPDH* are listed in [Table 2](#tab2){ref-type="table"}.

2.5. Primer Design and PCR Using the Sequenom MassARRAY System {#sec2.5}
--------------------------------------------------------------

The primers designed for*Nell-1* covered those regions with the most CpG sites. Most selected amplicons were located in the promoter region, from −581 to −137, relative to the transcription start site ([Figure 1](#fig1){ref-type="fig"}). The primers were designed using EpiDesigner \[[@B18]\]. For amplification, the reverse primer had a T7-promoter tag added, and the forward primer had a 10-mer tag sequence added to balance the PCR primer lengths (F: aaagagagGGTTTGGTTATTGTGGTTTGTTG and R: cagtaatacgactcactatagggagaaggctAACCATCATCCCCCTCAAAT). Genomic DNA was treated with bisulfite using an EpiTect Bisulfite Kit (Qiagen AG). The bisulfite-treated genomic DNA was then amplified under the following conditions: initial denaturation, 94°C for 4 min, then 45 cycles of 94°C for 20 s, 56°C for 30 s, and 72°C for 1 min, followed by 3 min at 72°C. The products were stored at 4°C for further analysis.

2.6. *In Vitro* Transcription and T-Cleavage (RNase A Digestion) Assay {#sec2.6}
----------------------------------------------------------------------

Shrimp alkaline phosphatase (SAP; Sequenom) was used to remove unincorporated dinucleotide triphosphates (dNTPs). The components were 1.7 *μ*L of RNase-free ddH~2~O and 0.3 *μ*L of SAP combined with the above PCR products. The mixture was incubated at 37°C for 20 min, 85°C for 5 min, and then at 4°C indefinitely. Using T7 R&DNA polymerase (Epicentre, Madison, WI), thymidine triphosphate was incorporated into the PCR product, finishing the transcription reaction. Ribonucleotides and dNTPs were used at concentrations of 1 and 2.5 mmol/L, respectively. RNase A (Sequenom) was added to the same reaction to cleave the transcripts (T-cleavage assay). The reaction mixture was incubated at 37°C for 3 h. To remove the phosphate backbone, the T-cleavage/RNase A assay reaction products were diluted with 20 *μ*L of RNase-free H~2~O and mixed with Clean Resin (Sequenom) before performing MS.

2.7. Mass Spectrometry {#sec2.7}
----------------------

The entire RNase A and clean resin-treated product was robotically dispensed onto silicon matrix preloaded chips (SpectroCHIP; Sequenom) and mass spectra were collected using a MassARRAY Compact MALDI-TOF Analyzer (Sequenom). The mass spectra methylation ratios were generated using EpiTYPER (ver. 4.0; Sequenom).

2.8. Statistical Methods {#sec2.8}
------------------------

The data were analyzed using the SPSS software (ver. 17 for Windows; IBM, Armonk, NY). An analysis of variance (ANOVA) was used to identify significant differences in methylation rates among the samples. All *P* values were two-sided; *P* \< 0.05 was considered to indicate statistical significance.

3. Results and Discussion {#sec3}
=========================

Increasing numbers of cancer deaths are projected to occur in Asia; this trend can be combatted by expanding knowledge of cancer control and the underlying genetic mechanisms \[[@B2]\]. Although much has been learned about the genetic causes of cancer, the details remain unclear \[[@B27]\].

In a previous study, MSP and BGS were used to analyze promoter methylation \[[@B28]\]; however, these methods have similar disadvantages. For this reason, Sequenom created a high-throughput quantitative assay for DNA methylation using MALDI-TOF MS and MassCLEAVE reagent. This method is highly accurate with regard to specific methylation sites, and it enables both quantitative assessment of methylation levels and analysis of multiple methylation sites \[[@B16], [@B24], [@B25], [@B29]\].

In this study, we analyzed the methylation patterns of the*Nell-1* gene in 25 gastric cancer tissue samples, 25 tissues adjacent to gastric cancer, and 25 normal samples. The*Nell-1* sequences analyzed contained CpG-rich regions. In total, 48 CpG sites per sample were analyzed. More than 50% of the CpG sites in*Nell-1* were detected in amplicons, and almost 80% of the CpG sites in the amplicons were used in our analysis ([Table 3](#tab3){ref-type="table"}).

The three types of samples showed different methylation levels at the various CpG sites in*Nell-1*. An ANOVA demonstrated significant differences in the methylation levels of*Nell-1* between the gastric cancer and normal samples (*P* \< 0.05 at 8 CpG sites and *P* \< 0.01 at 11 CpG sites). Additionally, significant differences were detected between the gastric cancer and paracarcinoma samples (*P* \< 0.05 at five CpG sites and *P* \< 0.01 at four CpG sites). However, there was no significant difference between the paracarcinoma and normal samples (eight CpG sites with *P* \< 0.05). Also, the gastric cancer samples had higher degrees of methylation relative to the normal samples ([Figure 2](#fig2){ref-type="fig"}). The abnormal methylation of DNA is an early event in carcinogenesis and can serve as a biomarker for early detection \[[@B30]\]. In this study, we demonstrated that the methylation level of*Nell-1* is an important issue in gastric cancer. This finding may be useful in the earliest stages of clinical disease. However, before considering the methylation status of the*Nell-1* promoter as a biomarker in gastric cancer and normal tissues, further research is needed. In cancer patients, promoter hypermethylation has some prognostic value. It has been reported that*Nell-1* binds to a specific membrane protein (APR3) to mediate the downregulation of cyclin D1 \[[@B31]\]. Based on a functional analysis of cell proliferation and osteoblast differentiation, APR3 binding may be the mechanism by which*Nell-1* promotes osteoblast differentiation \[[@B32]\]. Thus,*Nell-1*, as a suppressor gene may play a role in cancer metastasis.

We also found that the transcription and translation of*Nell-1* were decreased in the gastric cancer samples compared to the normal samples. This may be explained by the fact that the methylation of a gene can reduce its expression. Quantitative PCR showed that the mRNA expression of*Nell-1* in the gastric cancer tissues was decreased threefold compared with that in the normal tissues ([Figure 3](#fig3){ref-type="fig"}). As expected, immunohistochemical analyses of gastric cancer samples showed a lower intensity of*Nell-1* staining and that the cancer cells had spread to the muscle layer ([Figure 4](#fig4){ref-type="fig"}). The malignant transformation of gastric cells occurs via a multistep process involving various genetic and epigenetic changes \[[@B33]\]. The relationship between*Nell-1* methylation and*Nell-1* protein expression requires further confirmation. Transcriptional silencing of the*Nell-1* promoter is an early and common event in human EAC \[[@B23]\] and colon tumorigenesis \[[@B22]\]. Increased methylation of*Nell-1* may play a role in other cancers \[[@B34]\]. Our results indicate that the methylation level of the*Nell-1* promoter is related to the spread of gastric cancer cells.*Nell-1* expression was detected in normal and gastric cancer tissues, suggesting a physiological role in normal gastric tissues. It will be interesting to investigate the correlation of*Nell-1* promoter methylation with the transformation of gastric cancer cells and cancer prevention.

4. Conclusions {#sec4}
==============

MALDI-TOF MS is a useful tool for the analysis of DNA methylation. Methylation of the*Nell-1* promoter is a common event in gastric cancer compared with normal tissue.*Nell-1* promoter methylation reduced the expression of*Nell-1* in gastric cancer tissues, as determined by a lower intensity of IHC staining, with expansion to the muscle layer. This suggests that*Nell-1* can be used as a biomarker for the diagnosis of gastric cancer.

Funding for this study was provided by the National Natural Science Foundation of China (81200762) and Heilongjiang Province Natural Science Foundation (ZD200920). The authors gratefully acknowledge the assistance from Bioyong technologies Inc. and Beijing Compass Biotechnology Co., Ltd., for technical support.

MALDI-TOF MS:

:   Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry

IHC:

:   Immunohistochemistry

H&E:

:   Hematoxylin and eosin.

Conflict of Interests
=====================

The authors declare that there were no competing financial interests and no conflict of interests regarding the publication of this paper.

![Amplicon size and locations of informative CpG sites in amplicons of the*Nell-1* gene. (a) The sequences of targeted gene. The amplified region was colored in gray. Transcription start sequences were labeled in frame and transcription sites were labeled in yellow. CpG sites in amplicons appear in red and single line represented separate detection. Double line showed testing with the adjacent site. Point line showed adjacent three-site testing. No line showed that CpG sites cannot be detected in amplified sequences. (b) The amplicon map and the locations of CpG sites.](BMRI2015-136941.001){#fig1}

![CpG ratios of CpG sites in the*Nell-1* gene covered and not covered by MALDI-TOF MS analysis. Error bars and comparisons among tumour tissues, paracarcinoma tissues, and normal tissues are shown.](BMRI2015-136941.002){#fig2}

![*Nell-1* mRNA expression analysis. Quantitative polymerase chain reaction (qPCR) was performed to identify the mRNA expression of*Nell-1* in normal tissues and tumour tissues.](BMRI2015-136941.003){#fig3}

![Immunohistochemistry and hematoxylin and eosin staining of*Nell-1* protein expression (a, b) normal tissues; (c, d) mucosal layer of tumour tissues; (c\', d\') muscular layer of tumour tissues.](BMRI2015-136941.004){#fig4}

###### 

The clinical characteristics of study subjects.

  GC^a^   Gender   Age (year)   Differentiation   AJCC^b^ stage
  ------- -------- ------------ ----------------- ---------------
  GC01    Male     76           Poor              III
  GC02    Female   59           Poor              I
  GC03    Male     60           Moderate/poor     III
  GC04    Male     48           Poor              III
  GC05    Male     77           Moderate          II
  GC06    Female   69           Poor/mucinous     III
  GC07    Male     49           Poor/mucinous     III
  GC08    Female   58           Moderate/poor     II
  GC09    Male     54           Poor              I
  GC10    Female   70           Moderate/poor     III
  GC11    Male     52           Moderate          II
  GC12    Male     57           Poor/mucinous     III
  GC13    Female   52           Poor/mucinous     II
  GC14    Male     70           Moderate/poor     II
  GC15    Male     65           Moderate/poor     III
  GC16    Male     58           Poor              II
  GC17    Male     58           Moderate/poor     II
  GC18    Female   71           Poor              III
  GC19    Female   55           Poor              III
  GC20    Female   58           Poor              III
  GC21    Female   64           Poor              III
  GC22    Male     71           Moderate          I
  GC23    Male     50           Poor/mucinous     III
  GC24    Female   76           Moderate/poor     III
  GC25    Female   55           Moderate          I

^a^GC: gastric cancer; ^b^AJCC: the American Joint Committee on Cancer.

###### 

The primer sequences of *Nell-1* and GAPDH genes.

  Human gene   Forward primer sequence (5′ → 3′)   Reverse primer sequence (5′ → 3′)
  ------------ ----------------------------------- -----------------------------------
  *Nell-1*     GCTTTGGGATGGACCCTGAC                GAAATAAAAATGCTTTGCTGGC
  GAPDH        GTCTCCTCTGACTTCAACAGCG              ACCACCCTGTTGCTGTAGCC

###### 

MALDI-TOF MS analysis of CpG sites in amplicons of the *Nell-1* gene.

  --------------------------------------------------------------------------------------------------------------------------------
  Gene       Amplicon size (bp)   Total number of CpG\   Number of analyzed CpG\   Number of analyzed CpG sites in amplicon   
                                  sites in amplicon      sites in amplicon                                                    
  ---------- -------------------- ---------------------- ------------------------- ------------------------------------------ ----
  *Nell-1*   445                  48                     38                        17                                         21

  --------------------------------------------------------------------------------------------------------------------------------

[^1]: Academic Editor: Haiteng Deng
